Ranitidine and Pamine forte drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Ranitidine (ranitidine) and Pamine forte (methscopolamine bromide). Common drug interactions include depression among females.
The phase IV clinical study analyzes what interactions people have when they take Ranitidine and Pamine forte. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.
What is Ranitidine?
Ranitidine has active ingredients of ranitidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 234,475 Ranitidine users. Check the latest studies of Ranitidine.
What is Pamine forte?
Pamine forte has active ingredients of methscopolamine bromide. eHealthMe is studying from 71 Pamine forte users. Check the latest studies of Pamine forte.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
12 people who take Ranitidine and Pamine forte together, and have interactions are studied.
What are the common drug interactions of Ranitidine and Pamine Forte, by gender? *:
female:
- Depression
- Injection site haematoma (localized swelling filled with blood at injection site)
- Injection site haemorrhage (bleeding from injection site)
- Irritability
male:
n/a
What are the common drug interactions of Ranitidine and Pamine Forte, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
- Depression
- Injection site haematoma (localized swelling filled with blood at injection site)
- Injection site haemorrhage (bleeding from injection site)
- Irritability
60+:
n/a
What are the existing conditions these people have? *
- Primary Myelofibrosis (primary disorder of the bone marrow): 10 people, 83.33%
- Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 9 people, 75.00%
- Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 2 people, 16.67%
* Approximation only. Some reports may have incomplete information.
Do you take Ranitidine and Pamine forte?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
- Ranitidine (234,475 reports)
- Pamine forte (71 reports)
Browse all drug interactions of Ranitidine and Pamine forte:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Ranitidine:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Pamine forte:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Ranitidine and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Pamine forte and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on ranitidine and methscopolamine bromide (the active ingredients of Ranitidine and Pamine forte, respectively), and Ranitidine and Pamine forte (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Lortab cause Social Problem? - now
- Drug interactions of Glutathione and Carboplatin - 2 seconds ago
- Could Zyprexa cause Restless Leg Syndrome? - 7 seconds ago
- Drug interactions of Tolterodine Tartrate and Epinephrine - 8 seconds ago
- Could Tamsulosin Hydrochloride cause Adverse Event? - 16 seconds ago
- Could Ursodiol cause Cataract? - 20 seconds ago
- Drug interactions of Cilostazol and Tylenol - 22 seconds ago
- Drug interactions of Myrbetriq and Sumatriptan - 26 seconds ago
- Drug interactions of Azithromycin and Tradjenta - 32 seconds ago
- Could Firdapse cause Chest Pain? - 38 seconds ago